SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of “Hold” from Analysts

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) has earned a consensus rating of “Hold” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $52.57.

Several research firms have issued reports on SWTX. Cowen lowered shares of SpringWorks Therapeutics to a “hold” rating in a research report on Tuesday, April 29th. TD Cowen reiterated a “hold” rating and issued a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Evercore ISI cut SpringWorks Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 28th. Guggenheim reaffirmed a “neutral” rating and issued a $47.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th.

Insider Transactions at SpringWorks Therapeutics

In related news, COO Badreddin Edris sold 20,000 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the completion of the sale, the chief operating officer now directly owns 169,712 shares in the company, valued at $9,203,481.76. The trade was a 10.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Saqib Islam sold 49,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $54.24, for a total value of $2,657,760.00. Following the transaction, the chief executive officer now owns 954,869 shares in the company, valued at $51,792,094.56. The trade was a 4.88% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.83% of the company’s stock.

Institutional Trading of SpringWorks Therapeutics

Institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC raised its holdings in SpringWorks Therapeutics by 30.8% in the 4th quarter. Los Angeles Capital Management LLC now owns 61,760 shares of the company’s stock valued at $2,231,000 after acquiring an additional 14,548 shares in the last quarter. Schroder Investment Management Group grew its stake in SpringWorks Therapeutics by 93.6% during the fourth quarter. Schroder Investment Management Group now owns 168,209 shares of the company’s stock worth $6,113,000 after buying an additional 81,314 shares in the last quarter. Vanguard Group Inc. increased its holdings in SpringWorks Therapeutics by 6.6% in the 4th quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company’s stock valued at $258,650,000 after buying an additional 445,593 shares during the period. BIT Capital GmbH raised its position in shares of SpringWorks Therapeutics by 18.7% in the 4th quarter. BIT Capital GmbH now owns 53,539 shares of the company’s stock valued at $1,934,000 after buying an additional 8,429 shares in the last quarter. Finally, Platinum Investment Management Ltd. bought a new position in SpringWorks Therapeutics in the fourth quarter valued at approximately $1,694,000.

SpringWorks Therapeutics Price Performance

SpringWorks Therapeutics stock opened at $46.27 on Friday. The company has a market cap of $3.49 billion, a price-to-earnings ratio of -13.30 and a beta of 0.77. The firm has a 50-day moving average of $43.62 and a 200-day moving average of $42.59. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The company had revenue of $49.09 million during the quarter, compared to the consensus estimate of $64.19 million. As a group, sell-side analysts expect that SpringWorks Therapeutics will post -2.05 earnings per share for the current year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.